Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.26%
)
US TECH 100
29,592.40
(
0.20%
)
Dow Jones
51,078.88
(
0.09%
)
Brent Oil
94.14
(
-1.91%
)
Bitcoin
70,827.44
(
-0.76%
)
News Focus
News Focus
Post# of 257684
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123050
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gfp927z post# 30645

Tuesday, 06/27/2006 9:56:33 AM

Tuesday, June 27, 2006 9:56:33 AM

Post# of 257684
>Is Novartis the Future of Generics?<

After today’s announcement, BRL/Pliva may be the prototype for the future of generics. BRL CEO Bruce Downey says that, when the merger closes, BRL will be the clear #1 in biogenerics and will have vertical integration and low-cost (and low-tax) manufacturing that rivals anyone, including TEVA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up